Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

MARK ROBERT KEATON

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1477530533
CMS profile
21660
Location
FLORENCE, SC

General Payments · PY2018–2024

$28,689.36

  • Reported across 433 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$9,432.37

13 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $8,240.00 5
Travel and Lodging $1,080.26 5
Food and Beverage $112.11 3

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Acerta Pharma LLC $9,412.00 12
Kite Pharma, Inc. $20.37 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $3,189.03 193
PY2019 $5,477.15 182
PY2020 $4,861.15 31
PY2021 $1,942.50 1
PY2022 $3,462.59 6
PY2023 $324.57 7
PY2024 $9,432.37 13

Payment records · PY2024 (13)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
AstraZeneca Pharmaceuticals LP $1,665.00 01/22/2024 Consulting Fee Undisputed 01/23/2026 1105776282 CMS
AstraZeneca Pharmaceuticals LP $525.00 03/06/2024 Consulting Fee Undisputed 01/23/2026 1104581044 CMS
AstraZeneca Pharmaceuticals LP $23.56 06/30/2024 Travel and Lodging Undisputed 01/23/2026 1104321654 CMS
AstraZeneca Pharmaceuticals LP $179.67 06/30/2024 Travel and Lodging Undisputed 01/23/2026 1104398103 CMS
AstraZeneca Pharmaceuticals LP $45.80 06/30/2024 Travel and Lodging Undisputed 01/23/2026 1104473064 CMS
AstraZeneca Pharmaceuticals LP $41.49 06/30/2024 Food and Beverage Undisputed 01/23/2026 1104490102 CMS
AstraZeneca Pharmaceuticals LP $5,000.00 06/30/2024 Consulting Fee Undisputed 01/23/2026 1104622076 CMS
AstraZeneca Pharmaceuticals LP $106.50 06/30/2024 Travel and Lodging Undisputed 01/23/2026 1104671331 CMS
AstraZeneca Pharmaceuticals LP $724.73 06/30/2024 Travel and Lodging Undisputed 01/23/2026 1105222328 CMS
AstraZeneca Pharmaceuticals LP $50.25 06/30/2024 Food and Beverage Undisputed 01/23/2026 1105888159 CMS
AstraZeneca Pharmaceuticals LP $525.00 08/01/2024 Consulting Fee Undisputed 01/23/2026 1104313034 CMS
AstraZeneca Pharmaceuticals LP $525.00 08/26/2024 Consulting Fee Undisputed 01/23/2026 1105714092 CMS
Kite Pharma, Inc. $20.37 11/08/2024 Food and Beverage Undisputed 01/23/2026 1128612681 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.